Joseph Cambio, DO
Urology · West Warwick, RINPI 1558428540
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $9,006 of the $11,100 with a category attached, or 81.1%. 37 manufacturers reported payments, led by Teleflex LLC at 36.3% of the total.
Across 265 payments — averaging $41.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teleflex LLC$4K
- Procept Biorobotics Corporation$2K
- Axonics, Inc.$1K
- Astellas Pharma US Inc$682
- Neotract Inc.$659
- AbbVie$456
- plus $2K from 31 others
Across 1 payment — averaging $23,403 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- SRS Medical Systems, Inc.$23K
What the payments were for
- Travel & lodging$2,01618%
- Food & beverage$9,00681%
- Education$781%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teleflex LLC | 45 | $4,025 |
| Procept Biorobotics Corporation | 23 | $2,028 |
| Axonics, Inc. | 19 | $1,135 |
| Astellas Pharma US Inc | 46 | $682 |
| Neotract Inc. | 13 | $659 |
| AbbVie(2 entities) | 25 | $456 |
| Sumitomo Pharma America, Inc. | 22 | $438 |
| Boston Scientific | 3 | $142 |
| Johnson & Johnson | 7 | $132 |
| Pfizer | 6 | $124 |
| Endo Pharmaceuticals Inc. | 5 | $104 |
| Endo USA, Inc. | 3 | $97 |
| Antares Pharma, Inc. | 4 | $89 |
| Progenics Pharmaceuticals, Inc. | 3 | $78 |
| Immunitybio, Inc. | 3 | $75 |
| Blue Earth Diagnostics | 3 | $73 |
| Verity Pharmaceuticals Inc. | 2 | $67 |
| Coloplast | 3 | $66 |
| Sun Pharmaceutical Industries Inc. | 3 | $57 |
| Olympus America Inc. | 3 | $55 |
| Dendreon Pharmaceuticals LLC | 3 | $54 |
| Ferring Pharmaceuticals Inc. | 2 | $44 |
| Medtronic | 2 | $44 |
| Accord Healthcare, Inc. | 2 | $44 |
| Myovant Sciences Inc. | 3 | $44 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $40 |
| Ambu Inc. | 1 | $36 |
| Caris MPI, Inc. | 1 | $32 |
| 180 Medical, Inc. | 1 | $25 |
| Agiliti Surgical, Inc. | 1 | $24 |
| Merck | 1 | $21 |
| ABC Home Medical Supply, Inc. | 1 | $21 |
| Halozyme Inc | 1 | $20 |
| Palette Life Sciences, Inc. | 1 | $19 |
| AstraZeneca | 1 | $18 |
| Laborie Medical Technologies Corp. | 1 | $15 |
| Valencia Technologies Corporation | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UroLift$2,532
- AquaBeam Robotic System$1,275
- Axonics$313
- Bulkamid$233
- AQUABEAM SYSTEM$228
- Axonics r-SNM System$122
- Barrigel$121
- UroLift System$117
- AMS$107
How this compares
$11,100 in reported general payments places this provider in the 85th percentile of 55 urology providers in Rhode Island.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| GemtesaVibegron | 108 | $84,104 |
| MyrbetriqMirabegron | 126 | $77,756 |
| Tamsulosin Hcl | 834 | $11,402 |
| Finasteride | 655 | $8,392 |
| Trospium Chloride | 36 | $3,579 |
| Methenamine Hippurate | 31 | $2,673 |
| Oxybutynin Chloride ErOxybutynin Chloride | 108 | $2,517 |
| Cefpodoxime Proxetil | 36 | $1,137 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 64 | $1,104 |
| Potassium Citrate ErPotassium Citrate | 18 | $1,039 |
| Cephalexin | 176 | $884 |
| Doxazosin Mesylate | 36 | $708 |
| Oxybutynin Chloride | 42 | $518 |
| Dutasteride | 17 | $425 |
| Bicalutamide | 13 | $279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sumitomo Pharma America, Inc.Gemtesa | $438 | $84,104108 claims |
| Astellas Pharma US IncMyrbetriq | $682 | $77,756126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 55 urology providers in Rhode Island.
Other urology in West Warwick
- Mark LeoWest Warwick$13K
- Angelo CambioWest Warwick$9K
- Alexander LubinWest Warwick$5K
- Joseph CambioWest Warwick$4K
- Atip ChatsudthipongWest Warwick$855
- Vincent CatallozziWest Warwick$666
- Dicken KoProvidence$158K
- Gyan PareekProvidence$83K
- Joseph RenzulliProvidence$81K
- Simone ThavaseelanProvidence$16K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.